Treatment decisions for BC are mainly based on clinicopathological variables that are prognostic, such as tumor size, presence of lymph node metastasis, grading, and three predictive markers (ER, PR and HER2). The gene discussed is ERBB2; the disease is metastatic malignant neoplasm in the lymph nodes.